Photo of Dr. Hagop Kantarjian from obroncology.com
Apr 5, 2024, 08:22
Hagop Kantarjian: Low-dose azacitidine plus venetoclax – in patients with AML unable to complete standard consolidation strategies
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Low-dose azacitidine plus venetoclax maintains remissions with manageable side effects in patients with AML unable to complete standard consolidation strategies (2-year modified RFS and OS of 56% and 72%).”
Proceed to the article.
Source: Hagop Kantarjian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54